In an ongoing phase 2a open-label study of 49 patients with phlebotomy-dependent polycythaemia vera, 4-weekly sapablursen lowered the weekly phlebotomy rate by 0.10 in both the 120/80 mg and 40 mg cohorts (P≤.0001). Anaemia and fatigue were the commonest adverse events.
RCTn = 49
Palmer et al. Sapablursen for erythrocytosis control in patients with polycythemia vera